Revive Therapeutics Ltd C.RVV

Alternate Symbol(s): RVVTF

Healthcare

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).

CSE:RVV - Post by User

Revive Therapeutics Ltd > I'll make it a little more clear

<< Previous

Bullboard Posts

Next >>

Comment by PowerofNowon Aug 26, 2020 1:38pm

73 Views

Post# 31456533

RE:I'll make it a little more clear

mrnormal wrote:

You need an IRB to apply for compassionate use.

Revive JUST SUBMITTED the submission of the Phase 3 study protocol to Advarra, a premier IRB services. Advarra an IRB needs to approve this in order for Revive to submit for compassionate use with the FDA !!!

Come on people get your head in the game.

Advarra could respond within 24 hours

Then Revive will apply for compassionate use. FDA take take as little as 1-14 days to approve compassionate use.

Like I said, Bucillamine could be in use Mid-September.

But what do I know, right?!